Mitaclau (Desmopressin)

Desmopressin, the active ingredient in Mitaclau, is a vasopressin analog (antidiuretic hormone) presented as a sublingual formulation for sublingual use. It is employed to manage central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders by enhancing water reabsorption and promoting clotting factor release.

GNH USA supplies Mitaclau as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mitaclau acts on the vasopressin V2 receptor pathway to control water balance and support haemostasis. - Central diabetes insipidus: reduces excessive urine output and stabilises plasma osmolality. - Nocturnal enuresis: decreases nighttime urinary frequency in children and adults. - Hemophilia A: raises factor VIII levels to improve clot formation. - Von Willebrand disease: enhances von Willebrand factor release, aiding platelet adhesion and clot stability.

Desmopressin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nasal congestion or irritation (if administered intranasally). - Nausea or abdominal discomfort. - Mild hyponatraemia: low sodium levels without severe symptoms. - Flushing or warmth sensation. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Severe hyponatraemia: can lead to seizures, coma, or cerebral oedema. - Water intoxication: excessive fluid retention causing rapid weight gain. - Allergic reactions: rash, itching, or anaphylaxis. - Thrombotic events: rare clot formation in predisposed individuals. - Cardiac arrhythmias: associated with electrolyte disturbances. - Hypertension: sudden increase in blood pressure.

Before using Mitaclau, consider the following safety measures. - Assess fluid balance: monitor intake and output to avoid water overload. - Check serum sodium: baseline and periodic testing are recommended, especially in the elderly. - Review concomitant medications: avoid drugs that may exacerbate hyponatraemia, such as thiazide diuretics. - Caution in renal impairment: dose adjustments may be required. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Desmopressin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with vasopressin antagonists (e.g., conivaptan) may negate therapeutic effect. - Co‑administration with carbamazepine or phenytoin can markedly reduce plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen) may increase risk of hyponatraemia. - Loop or thiazide diuretics can potentiate water‑electrolyte disturbances. - Antihypertensives (e.g., ACE inhibitors) may enhance hypotensive effects. - Antidepressants (e.g., SSRIs) may contribute to electrolyte imbalance.